Cat No.
CEI-0838
Description
Tyrphostin 9 is firstly designed as an EGFR inhibitor with IC50 of 460 μM, but is also found to be more potent to PDGFR with IC50 of0.5μM.
Alias
Tyrphostin AG 17, Malonaben, NSC 242557, RG-50872
Synonyms
Tyrphostin AG 17, Malonaben, NSC 242557, RG-50872
CAS No.
10537-47-0
IC50
460 μM
Targets
EGFR, PDGFR
Chemical Name
Propanedinitrile, 2-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]methylene]-
M.Wt
282.38
Solubility
DMSO 56 mg/mL; Water <1 mg/mL; Ethanol 56 mg/mL
Storage
2 years -20 centigrade Powder; 2 weeks 4 centigrade in DMSO; 6 months -80 centigrade in DMSO.
In vitro
SF 6847 inhibits the replication of herpes simplex virus type 1 (HSV-1) with IC50 of 40 nM. SF 6847 (50 nM) partly reverses sodium orthovanadate induced HSV-1 plaque formation. SF 6847 (< 400 nM) decreases the phosphorylation of viral phosphoproteins in a dose-dependent manner, but the SF 6847 (< 800 nM)-induced reduction of protein synthesis is not dose-dependent.SF 6847 prevents PDGF-induced tyrosine phosphorylation of LRP in caveolae in human fibroblasts suggesting that PDGF-BB-mediated LRP activation requires tyrosine phosphorylation and therefore activation of PDGFR-β.SF 6847 (1 mM) blocks the strain-induced stimulatory effect on DNA synthesis of fetal lung cells.SF 6847 (1 μM) causes increased exon inclusion of MAPT exon 10. SF 6847 does not affect the translation or stability of the two mRNAs. SF 6847 (1.6 μM) increases the inclusion of MAPT exon 10 by 2-fold in SHSY-5Y cells.
